welcome to oneFAPvoice- a positively charged Familial Adenomatous Polyposis community.
- join today!
A Study of Rofecoxib in Familial Adenomatous Polyposis (FAP)
study id #: NCT00140894
condition: Adenomatous Polyposis Coli
A study to evaluate rofecoxib in the treatment of rectal, colon, or duodenal adenomas in patients with Familial Adenomatous Polyposis.
Drug: MK0966; rofecoxib / Duration of Treatment: 24 weeks
Drug: Comparator: placebo / Duration of Treatment: 24 weeks
start date: March 2003
estimated completion: Not Available
last updated: September 29, 2017
phase of development: Phase 4
size / enrollment: 62
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Primary Purpose: Treatment
- Number and average size of rectal polyps
- Safety and tolerability
- Number and average size of duodenal polyps
- Proportions of patients with improved overall colon rating
- Males or females at least 18 years of age with familial adenomatous polyposis.
expertly curated content related to this topic
Familial Risk-Colorectal Cancer: ESMO Clinical Practice GuidelinesLynch syndrome is the most common heredi...
Bonnies Diary Oct 07https://jtvcancersupport.com/embed/26553...
Chemoprevention of Colorectal CancerColorectal cancer has become one of the ...
Dietary Polyamine Intake and Risk of Colorectal Adenomatous PolypsBACKGROUND : Putrescine, spermidine, and...
Dual Focus NBI and pCLE in FAP Related Duodenal AdenomaBackground: Familial adenomatous pol...